Q1 EPS Estimate for MiNK Therapeutics Lifted by Analyst

MiNK Therapeutics, Inc. (NASDAQ:INKT) – HC Wainwright boosted their Q1 2026 earnings estimates for shares of MiNK Therapeutics in a research note issued to investors on Wednesday, April 1st. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of ($0.77) per share for the quarter, up from their prior forecast of ($0.78). HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for MiNK Therapeutics’ current full-year earnings is ($2.75) per share. HC Wainwright also issued estimates for MiNK Therapeutics’ Q2 2026 earnings at ($0.87) EPS, Q3 2026 earnings at ($0.91) EPS, Q4 2026 earnings at ($0.95) EPS, FY2026 earnings at ($3.50) EPS, FY2027 earnings at ($3.58) EPS, FY2028 earnings at ($1.27) EPS and FY2029 earnings at ($0.12) EPS.

MiNK Therapeutics (NASDAQ:INKT) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.14.

Separately, Wall Street Zen upgraded shares of MiNK Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, January 19th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, MiNK Therapeutics has a consensus rating of “Hold” and an average target price of $35.00.

MiNK Therapeutics Price Performance

Shares of NASDAQ INKT opened at $10.69 on Friday. The stock has a market capitalization of $53.13 million, a P/E ratio of -3.60 and a beta of 0.35. The business’s 50 day moving average is $10.85 and its two-hundred day moving average is $12.18. MiNK Therapeutics has a 1-year low of $6.34 and a 1-year high of $76.00.

Institutional Investors Weigh In On MiNK Therapeutics

An institutional investor recently bought a new position in MiNK Therapeutics stock. DRW Securities LLC purchased a new position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 25,677 shares of the company’s stock, valued at approximately $286,000. DRW Securities LLC owned about 0.55% of MiNK Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 2.87% of the company’s stock.

MiNK Therapeutics News Roundup

Here are the key news stories impacting MiNK Therapeutics this week:

• Positive Sentiment: MiNK will present investigator-initiated Phase II data on agenT-797 in combination with botensilimab and balstilimab at the AACR annual meeting (April 17–22). Positive or encouraging AACR data could drive renewed investor interest in the company’s solid-tumor program and partner-combination potential. MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026
• Positive Sentiment: An abstract on agenT-797 was accepted for presentation at the ASGCT Annual Meeting (May). Acceptance at major scientific conferences raises visibility with researchers, potential collaborators and investors—helpful for a development-stage biotech seeking partnerships or licensing interest. MiNK Therapeutics’ AgenT-797 Abstract Accepted for Presentation at ASGCT Annual Meeting 2026
• Positive Sentiment: HC Wainwright reiterated a Buy rating and a $35 price target on INKT—continued buy-side coverage and a meaningful target can support investor confidence and act as a positive sentiment anchor. MiNK Therapeutics (NASDAQ:INKT) Earns Buy Rating from HC Wainwright
• Neutral Sentiment: HC Wainwright updated several near-term EPS estimates (small upward revisions for Q1–Q3 2026 and FY2026–28), reflecting model-level adjustments rather than a change in recommendation; these tweaks marginally improve near‑term outlook but do not remove development risk. (No single linked article provided for the detailed estimate changes.)
• Negative Sentiment: HC Wainwright lowered its Q4 2026 EPS estimate slightly and materially cut its FY2029 estimate (from a positive $0.49 to ($0.12)), signaling longer‑term uncertainty in revenue/timing assumptions—this could weigh on valuation models that previously assumed later‑stage commercial upside.
• Neutral Sentiment: Trading remains light today compared with average volume and the stock sits well below its 12‑month high; until AACR/ASGCT data are public or a clear commercial path emerges, expect muted price action and higher sensitivity to headline risk.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.